External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies

Abstract Background Prostate-specific membrane antigen (PSMA)-targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiatio...

Full description

Bibliographic Details
Main Authors: J. Kurth, B. J. Krause, S. M. Schwarzenböck, L. Stegger, M. Schäfers, K. Rahbar
Format: Article
Language:English
Published: SpringerOpen 2018-04-01
Series:EJNMMI Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13550-018-0386-4